Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMFOVSD)

Drug Name
Brompheniramine Drug Info
Synonyms
Bromfed; Bromfenex; Bromfeniramina; Brotane; Parabromdylamine; BROMFED-DM; Bromfeniramina [INN-Spanish]; Brompheniramine (INN); Brompheniramine [INN:BAN]; Brompheniraminum [INN-Latin]; Brotane (TN); DIMETANE-DX; P-Bromdylamine; Para-Bromdylamine; Brompheniramine Maleate (1:1); [3-(4-Bromophenyl)-3-(2-pyridyl)propyl]dimethylamine; Gamma-(4-Bromophenyl)-N,N-dimethyl-2-pyridinepropanamine; 1-(p-Bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 2-(p-Bromo-alpha-(2-dimethylaminoethyl)benzyl)pyridine; 3-(4-Bromophenyl)-N,N-dimethyl-3-(2-pyridinyl)-1-propanamine; 3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; 3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; 3-(p-Bromophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine
Therapeutic ClassAntiallergic Agents
Cross-matching ID
PubChem CID
6834
ChEBI ID
CHEMBL811
CAS Number
CAS 86-22-6
TTD Drug ID
D08VXO

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Complement and coagulation cascades 2.48 0.00e+0 76/85 (89.41%) C5;C9;C1S;...
TGF-beta signaling pathway 2.00 1.19e-2 81/94 (86.17%) GREM1;LEFTY1;INHBE;...
Mineral absorption 1.97 7.95e-3 48/60 (80%) MT1H;MT1X;ATP1A1;...
Primary bile acid biosynthesis 1.96 5.96e-3 15/17 (88.24%) CH25H;CYP39A1;CYP7A1;...
Porphyrin and chlorophyll metabolism 1.84 1.75e-2 23/43 (53.49%) UGT2B4;CP;UGT2B17;...
Melanoma 1.83 1.72e-2 68/72 (94.44%) CDH1;PDGFRA;KRAS;...
Bile secretion 1.82 1.82e-2 68/90 (75.56%) UGT2B4;ATP1A1;UGT2B17;...
Ascorbate and aldarate metabolism 1.80 1.79e-2 15/30 (50%) UGT2B4;UGT2B17;UGT2B15;...
Chronic myeloid leukemia 1.67 4.77e-2 72/76 (94.74%) MECOM;KRAS;HDAC1;...
Amoebiasis -1.63 4.03e-2 99/102 (97.06%) TGFB3;PIK3R3;CASP3;...
Antigen processing and presentation -1.63 4.18e-2 60/78 (76.92%) B2M;HLA-F;HSPA6;...
Allograft rejection -1.64 4.07e-2 32/38 (84.21%) HLA-E;HLA-F;PRF1;...
Retrograde endocannabinoid signaling -1.64 4.23e-2 118/148 (79.73%) NDUFV1;NDUFA4;KCNJ5;...
Diabetic cardiomyopathy -1.65 4.06e-2 162/203 (79.8%) CAMK2G;COX6A2;NDUFA7;...
Primary immunodeficiency -1.65 4.03e-2 33/38 (86.84%) CD3E;ZAP70;RAG1;...
Rheumatoid arthritis -1.66 3.84e-2 78/93 (83.87%) CXCL12;CSF2;ATP6V1E1;...
IL-17 signaling pathway -1.67 3.79e-2 84/94 (89.36%) MMP1;ELAVL1;FOS;...
Proteasome -1.67 3.86e-2 44/46 (95.65%) PSMD9;PSMB2;PSMD6;...
Human T-cell leukemia virus 1 infection -1.68 3.94e-2 197/219 (89.95%) CD3E;TGFB3;B2M;...
Huntington disease -1.68 3.96e-2 233/306 (76.14%) CASP9;ACTR10;NDUFV1;...
Fanconi anemia pathway -1.70 3.29e-2 36/54 (66.67%) ERCC1;BLM;FAN1;...
Th1 and Th2 cell differentiation -1.71 3.49e-2 80/92 (86.96%) CD3E;TBX21;ZAP70;...
Non-alcoholic fatty liver disease -1.72 3.17e-2 126/155 (81.29%) IL1B;NDUFS8;NDUFS3;...
Mismatch repair -1.74 2.97e-2 22/23 (95.65%) POLD4;RFC3;POLD1;...
Asthma -1.74 3.20e-2 25/31 (80.65%) PRG2;RNASE3;HLA-DRB1;...
Viral myocarditis -1.75 2.77e-2 53/60 (88.33%) EIF4G1;HLA-F;PRF1;...
Citrate cycle (TCA cycle) -1.77 2.16e-2 30/30 (100%) CS;MDH2;DLST;...
Regulation of lipolysis in adipocytes -1.78 2.02e-2 52/55 (94.55%) GNAI3;PIK3CA;ADRB3;...
Ovarian steroidogenesis -1.79 1.98e-2 41/51 (80.39%) PLA2G4C;ADCY2;PRKACB;...
Graft-versus-host disease -1.81 1.49e-2 32/42 (76.19%) HLA-E;IL1B;HLA-F;...
Oxidative phosphorylation -1.83 1.19e-2 93/133 (69.92%) NDUFV1;NDUFA4;NDUFA1;...
Nucleotide excision repair -1.87 1.19e-2 40/47 (85.11%) ERCC5;XPA;ERCC8;...
Type I diabetes mellitus -1.87 1.43e-2 38/43 (88.37%) HLA-E;IL1B;HLA-F;...
Prion disease -1.91 1.49e-2 209/273 (76.56%) IL1B;NDUFS8;NDUFS3;...
Hematopoietic cell lineage -1.94 1.19e-2 90/99 (90.91%) IL1B;CD59;CD3E;...
DNA replication -2.10 0.00e+0 34/36 (94.44%) POLD4;POLE2;RNASEH1;...
Parkinson disease -2.18 0.00e+0 176/249 (70.68%) CASP9;NDUFV1;NDUFA4;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.37uM - 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H